2. Academic Validation
  3. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

  • Mol Cell. 2019 Dec 5;76(5):838-851.e5. doi: 10.1016/j.molcel.2019.08.028.
Pei-Hsuan Chen 1,  Ling Cai 2,  Kenneth Huffman 3,  Chendong Yang 1,  Jiyeon Kim 1,  Brandon Faubert 1,  Lindsey Boroughs 1,  Bookyung Ko 1,  Jessica Sudderth 1,  Elizabeth A McMillan 4,  Luc Girard 5,  Dong Chen 6,  Michael Peyton 3,  Misty D Shields 3,  Bo Yao 7,  David S Shames 8,  Hyun Seok Kim 4,  Brenda Timmons 3,  Ikuo Sekine 3,  Rebecca Britt 3,  Stephanie Weber 3,  Lauren A Byers 9,  John V Heymach 9,  Jing Chen 6,  Michael A White 4,  John D Minna 10,  Guanghua Xiao 7,  Ralph J DeBerardinis 11
Affiliations

Affiliations

  • 1 Children's Medical Center Research Institute at UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • 2 Children's Medical Center Research Institute at UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; Quantitative Biomedical Research Center, Department of Population and Data Sciences at UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • 3 Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • 4 Department of Cell Biology, UTSW Medical Center, Dallas, TX 75390, USA.
  • 5 Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390 USA.
  • 6 Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • 7 Quantitative Biomedical Research Center, Department of Population and Data Sciences at UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • 8 Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA 94080, USA.
  • 9 Department of Thoracic/Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
  • 10 Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390 USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
  • 11 Children's Medical Center Research Institute at UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA. Electronic address: [email protected].
PMID: 31564558 DOI: 10.1016/j.molcel.2019.08.028
Abstract

Intermediary metabolism in Cancer cells is regulated by diverse cell-autonomous processes, including signal transduction and gene expression patterns, arising from specific oncogenotypes and cell lineages. Although it is well established that metabolic reprogramming is a hallmark of Cancer, we lack a full view of the diversity of metabolic programs in Cancer cells and an unbiased assessment of the associations between metabolic pathway preferences and other cell-autonomous processes. Here, we quantified metabolic features, mostly from the 13C enrichment of molecules from central carbon metabolism, in over 80 non-small cell lung Cancer (NSCLC) cell lines cultured under identical conditions. Because these cell lines were extensively annotated for oncogenotype, gene expression, protein expression, and therapeutic sensitivity, the resulting database enables the user to uncover new relationships between metabolism and these orthogonal processes.

Keywords

(13)C stable isotope labeling; cancer metabolism; cell lines; gene expression; glucose; glutamine; non-small cell lung cancer; oncogenotypes; protein expression; therapeutic sensitivity.

Figures
Products